Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Bladder cancer treatment depends on whether it is superficial or muscle invasive. Muscle-invasive bladder cancer or MIBC does ...

Kolschowsky Research and Education Institute at Sarasota Memorial Hospital is seeking candidates diagnosed with ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) significantly improved event-free survival (EFS) and overall survival (OS) in ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

US biotech ImmunityBio announced that treatment with Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free ...

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...

—A retrospective real-world study of patients with muscle-invasive bladder cancer showed that robot-assisted and laparoscopic radical cystectomy reduce post-surgical complication rates, compared to ...

Partial cystectomy is a surgical bladder-sparing option for selected patients with muscle-invasive bladder cancer (MIBC), urachal adenocarcinoma and diverticular bladder tumors. Partial cystectomy ...